Therapeutic indications

Ataluren is indicated for:

Duchenne muscular dystrophy

Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Ataluren is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.

The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

For this indication, competent medicine agencies globally authorize below treatments (click for details):


Ataluren is contraindicated in the following cases:





Severe renal impairment, end-stage renal disease

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Intravenous aminoglycosides

Aminoglycoside antibacterials

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines